-1(1).png)
.png)
.png)
ABSTRACT
To determine the effects of sibutramine in combination with hypocaloric diet and exercise on body composition, metabolic parameters and insulin resistance. 11 female, 1 male (aged 18-60 year) patients were enrolled. Sibutramine (10 mg/day), hypocaloric mixed diet and exercise were given. Analysis of antropometric measurements and bioimpedance measurements for estimating body composition, metabolic (uric acid, cholesterol, triglyceride, HDL-cholestrol) and hormonal (total and free testosterone, DHEAS, cortisol, growth hormone, prolactin) measurements and the determination of insulin resistance by euglycemic hyperinsulinemic clamp technique were done before and after the patients lost 10 % of their initial body weight. After weight loss, decrease in body weight (from 102,0±4,9 to 89,8±4,4 p<0,001), waist circumference (from 110,0±2,7 to 97,9±3,6 p>0,001) WHR (from 0,85±0,02 to 0,79±0,02 p<0,05) were significant. In impedance measurements, decrease of body fat mass (from 48±2,2 % to 41,1±2,2 % p<0,001) increase of lean body mass (from 51,9±2,2 % to 58,6±2,1 % p<0,001) and decrease of level of uric acid (from 5,3±0,4 to 4,8±0,3 p<0,05), triglyceride (from 126,2±23,7 to 98,0±17,2 p<0,01), cortisol (from 18,9±1,9 to 11,6±1,0 p<0,05), C-peptide (4,7±1,0 to 2,6±2,6 p<0,05) and 120 min glucose concentration (from 107,5±3,5 to 9,1±6,3 p<0,05) were significant. In euglycemic hyperinsulinemic clamp study, whole body glucose disposal (M value) increased significantly (from 2,87±0,27 to 4,26±0,41 p<0,01). Although the patients didnt reached ideal body weight, sibutramine assisted weight reduction of %10 caused meaningful reductions in BMI, WHR, triglyceride, fasting Cpeptide, cortisol level and significant improvement in insulin resistance.
To determine the effects of sibutramine in combination with hypocaloric diet and exercise on body composition, metabolic parameters and insulin resistance. 11 female, 1 male (aged 18-60 year) patients were enrolled. Sibutramine (10 mg/day), hypocaloric mixed diet and exercise were given. Analysis of antropometric measurements and bioimpedance measurements for estimating body composition, metabolic (uric acid, cholesterol, triglyceride, HDL-cholestrol) and hormonal (total and free testosterone, DHEAS, cortisol, growth hormone, prolactin) measurements and the determination of insulin resistance by euglycemic hyperinsulinemic clamp technique were done before and after the patients lost 10 % of their initial body weight. After weight loss, decrease in body weight (from 102,0±4,9 to 89,8±4,4 p<0,001), waist circumference (from 110,0±2,7 to 97,9±3,6 p>0,001) WHR (from 0,85±0,02 to 0,79±0,02 p<0,05) were significant. In impedance measurements, decrease of body fat mass (from 48±2,2 % to 41,1±2,2 % p<0,001) increase of lean body mass (from 51,9±2,2 % to 58,6±2,1 % p<0,001) and decrease of level of uric acid (from 5,3±0,4 to 4,8±0,3 p<0,05), triglyceride (from 126,2±23,7 to 98,0±17,2 p<0,01), cortisol (from 18,9±1,9 to 11,6±1,0 p<0,05), C-peptide (4,7±1,0 to 2,6±2,6 p<0,05) and 120 min glucose concentration (from 107,5±3,5 to 9,1±6,3 p<0,05) were significant. In euglycemic hyperinsulinemic clamp study, whole body glucose disposal (M value) increased significantly (from 2,87±0,27 to 4,26±0,41 p<0,01). Although the patients didnt reached ideal body weight, sibutramine assisted weight reduction of %10 caused meaningful reductions in BMI, WHR, triglyceride, fasting Cpeptide, cortisol level and significant improvement in insulin resistance.